Epilepsy with Myoclonic-Atonic Seizures: A Patient Guide

Epilepsy with myoclonic-atonic seizures (EMAtS), historically known as Doose syndrome, is a rare childhood epilepsy syndrome that typically begins between the ages of two and four. For most families, the diagnosis comes as a profound shock because the condition often emerges suddenly in children who were previously meeting their developmental milestones. This shift from a healthy childhood to one marked by frequent, unpredictable seizures can be overwhelming, but understanding the unique “rhythm” of this syndrome is the first step in regaining a sense of control over your child’s care ^[1][2].

The condition is defined by its hallmark “drop attacks”—lightning-fast events where a brief muscle jerk is followed by a sudden loss of muscle tone, causing the child to fall without warning. These seizures often arrive as part of a severe “stormy phase,” a term many clinicians use to describe a period shortly after diagnosis where seizures become very frequent and may be joined by other types, such as staring spells or convulsions. Because these falls are so sudden, day-to-day life often revolves around immediate physical safety, including the medically guided use of protective helmets and the creation of a highly detailed, individualized Seizure Action Plan to manage emergencies ^[3][4].

Treatment for EMAtS can be complex because the brain’s electrical activity may be resistant to standard medications. While several antiseizure drugs (like valproate or clobazam) are commonly used, the medical ketogenic diet is increasingly considered a core, early-line treatment option. This specialized high-fat diet has shown remarkable effectiveness in observational studies for stabilizing the brain and reducing seizures for many children. Because some common epilepsy medications can paradoxically make EMAtS seizures worse, working with a specialized comprehensive epilepsy center that understands these nuances is essential ^[5][6].

The long-term outlook for children with EMAtS is variable but often hopeful. In long-term studies, approximately 60% of children eventually achieved complete seizure freedom, often transitioning off their treatments after a period of prolonged stability. However, a significant portion of children continue to experience drug-resistant seizures, and the condition can impact cognitive development. Throughout this journey, the focus must remain on “the whole child”—monitoring their learning, speech, and behavior to ensure they have the support needed to navigate the developmental challenges that may arise ^[1][5].